• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, May 18, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Breakthrough in treatment for Dupuytren’s disease

Bioengineer by Bioengineer
April 29, 2022
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early stage Dupuytren’s disease.

Dupuytren's research - results of the RIDD trial

Credit: Emma Jackson

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early stage Dupuytren’s disease.

“This phase 2b trial represents the clinical translation of our laboratory findings, where we identified TNF as a potential therapeutic target followed by a phase 2a dose ranging trial which showed that the highly concentrated formulation injected directly into the diseased tissues was effective in downregulating myofibroblasts, the cells responsible for fibrosis,” said Jagdeep Nanchahal, Oxford Professor of Hand, Plastic and Reconstructive Surgery. “We also found the treatment to be completely safe and there were no related serious adverse events.”

Dupuytren’s disease is a common condition of the hand that affects about 5% of the UK population and tends to run in families. It causes the fingers to curl irreversibly into the palm and can be extremely disabling. There is currently no treatment for early disease and typically people have to wait until the condition deteriorates when surgery can be performed.

The trial recruited 140 participants with early-stage Dupuytren’s disease who were randomised to receive 4 injections at 3 monthly intervals of either adalimumab (40mg adalimumab in 0.4ml) or saline. The primary outcome was nodule hardness measured at 12 months, and patients were followed up for a total of 18 months.

Published in The Lancet Rheumatology, the study found that the patients receiving adalimumab experienced softening and reduction in size of the treated nodule. Although adalimumab only has a half-life of about two or three weeks the researchers saw continued effects nine months after the last injection, indicating a sustained treatment effect.

“This could be a game-changer for patients who suffer from this disabling condition,” said Professor Chris Buckley, Director of Clinical Research at the Kennedy Institute. “Dupuytren’s disease is easy to spot at an early stage, so by starting a course of anti-TNF injections could bring long lasting respite and prevent the disease advancing to the stage that surgery is needed.”

The research was funded by the Health Innovation Challenge Fund (Wellcome Trust, Department of Health and Social Care) and 180 Life Sciences.



Journal

The Lancet Rheumatology

DOI

10.1016/S2665-9913(22)00093-5

Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Article Title

Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Article Publication Date

29-Apr-2022

Share12Tweet8Share2ShareShareShare2

Related Posts

Health decline during pandemic

Aging well in a pandemic: Older adults share what it takes

May 17, 2022
mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

May 17, 2022

Henry Ford cardiologist to perform a live heart procedure at International Medical Education event

May 17, 2022

Scientists use machine learning models to help identify long COVID patients

May 17, 2022

POPULAR NEWS

  • Weybourne Atmospheric Observatory

    Breakthrough in estimating fossil fuel CO2 emissions

    46 shares
    Share 18 Tweet 12
  • Hidden benefit: Facemasks may reduce severity of COVID-19 and pressure on health systems, researchers find

    44 shares
    Share 18 Tweet 11
  • Discovery of the one-way superconductor, thought to be impossible

    43 shares
    Share 17 Tweet 11
  • Sweet discovery could drive down inflammation, cancers and viruses

    42 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Weather/StormsUrbanizationVaccinesVirusWeaponryUrogenital SystemVaccineZoology/Veterinary ScienceViolence/CriminalsVirologyUniversity of WashingtonVehicles

Recent Posts

  • Pancharatnam–Berry phase reversal via opposite-chirality-coexisted superstructures
  • Reliable diagnostics at the tip of your finger
  • Seafloor animal cued to settle, transformed by a bacterial compound
  • Tooth unlocks mystery of Denisovans in Asia
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....